ALT Altimmune, Inc.

Altimmune, Inc. (NASDAQ: ALT) is a late-stage clinical biotech company headquartered in Gaithersburg, Maryland, developing pemvidutide (ALT-801), a dual GLP-1/glucagon receptor agonist with a balanced 1:1 mechanism designed for metabolic diseases.

OTLK Outlook Therapeutics, Inc.

Binary Event Analysis: Outlook Therapeutics (OLTK) faces a critical PDUFA decision on December 31, 2025, for ONS-5010 (LYTENAVA™), a bevacizumab biosimilar for wet age-related macular degeneration (wet AMD).

RGNX REGENXBIO 

Currently at channel support , technically a good entry point . REGENXBIO Inc. (RGNX) is facing a landmark FDA decision on February 8, 2026 regarding approval of RGX-121 (clemidsogene lanparvovec), a one-shot AAV gene therapy for MPS II (Hunter Syndrome).

Aldeyra Therapeutics dec 16 PDUFA

Aldeyra Therapeutics (ALDX) – Comprehensive PDUFA Report ?? ?? Aldeyra Therapeutics Ticker ALDX PDUFA Date December 16, 2025 Current Price ~$5.16 Report Date November 21, 2025 ? Executive Summary Aldeyra Therapeutics (ALDX) is approaching a pivotal catalyst: a binary FDA…

NVRI Enviri Corporation

Enviri Corporation Announces Sale of Clean Earth to Veolia for $3.04 Billion and Taxable Spin-Off of Harsco Environmental and Rail Businesses ("New Enviri") to Shareholders

NUVB Oncology Breakout

?? EN ?? IT ✅ NUVB — Oncology Breakout & Commercial Growth Story IBTROZI FDA Approval Success | Q3 Revenue +100% Beat | TRUST-IV Phase 3 Catalyst | $549M Cash | +111% YTD Performance Nuvation Bio — Approved PK activator…

KZIA

KZIA Stock Analysis: Biotech Breakthrough in Triple-Negative Breast Cancer | Kazia Therapeutics ?? EN ?? IT ⚡ KZIA — The Breakthrough Moment Immune-Complete Response (iCR) Achieved | Stage IV Metastatic TNBC | +51% Surge on iCR Announcement Kazia Therapeutics —…

Comparative Catalysts and Trade Ideas

Discover comparative catalyst analysis for biotech stocks. This guide provides real-time trading insights comparing FDA PDUFA timelines, pipeline catalysts, and price targets across multiple small-cap pharmaceutical companies. Comparative Catalyst Report – EBS, RIGL, BNBX, DFDV Comparative Catalyst Report EBS |…